Organon Co Stock EBITDA
| OGN Stock | USD 15.30 0.05 0.33% |
Organon Co fundamentals help investors to digest information that contributes to Organon's financial success or failures. It also enables traders to predict the movement of Organon Stock. The fundamental analysis module provides a way to measure Organon's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Organon stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 1.4 B | 2.2 B |
Organon | EBITDA |
Organon Co Company EBITDA Analysis
Organon's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Organon EBITDA | 1.44 B |
Most of Organon's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Organon Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Organon EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Organon is extremely important. It helps to project a fair market value of Organon Stock properly, considering its historical fundamentals such as EBITDA. Since Organon's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Organon's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Organon's interrelated accounts and indicators.
Click cells to compare fundamentals
Organon EBITDA Historical Pattern
Today, most investors in Organon Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Organon's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Organon ebitda as a starting point in their analysis.
Organon EBITDA |
| Timeline |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Organon Ebitda
Ebitda |
|
According to the company disclosure, Organon Co reported earnings before interest,tax, depreciation and amortization of 1.44 B. This is 63.66% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 63.17% higher than that of the company.
Organon EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Organon's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Organon could also be used in its relative valuation, which is a method of valuing Organon by comparing valuation metrics of similar companies.Organon is currently under evaluation in ebitda category among its peers.
Organon ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Organon's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Organon's managers, analysts, and investors.Environmental | Governance | Social |
Organon Institutional Holders
Institutional Holdings refers to the ownership stake in Organon that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Organon's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Organon's value.| Shares | Charles Schwab Investment Management Inc | 2024-09-30 | 3.3 M | Citadel Advisors Llc | 2024-09-30 | 2.9 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.7 M | Acadian Asset Management Llc | 2024-09-30 | 2.6 M | Aqr Capital Management Llc | 2024-09-30 | 2.5 M | Slate Path Capital Lp | 2024-09-30 | 2.5 M | Thompson, Siegel & Walmsley Llc | 2024-09-30 | 2.3 M | Private Management Group Inc | 2024-09-30 | 1.9 M | Kahn Brothers & Co Inc /de/ | 2024-09-30 | 1.8 M | Blackrock Inc | 2024-06-30 | 32.6 M | Vanguard Group Inc | 2024-09-30 | 30.2 M |
Organon Fundamentals
| Return On Asset | 0.0791 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 12.02 B | ||||
| Shares Outstanding | 257.54 M | ||||
| Shares Owned By Insiders | 0.18 % | ||||
| Shares Owned By Institutions | 81.70 % | ||||
| Number Of Shares Shorted | 13.68 M | ||||
| Price To Earning | 4.20 X | ||||
| Price To Book | 8.02 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 6.26 B | ||||
| Gross Profit | 3.89 B | ||||
| EBITDA | 1.44 B | ||||
| Net Income | 1.02 B | ||||
| Cash And Equivalents | 706 M | ||||
| Cash Per Share | 2.14 X | ||||
| Total Debt | 8.76 B | ||||
| Current Ratio | 1.58 X | ||||
| Book Value Per Share | 1.91 X | ||||
| Cash Flow From Operations | 799 M | ||||
| Short Ratio | 4.25 X | ||||
| Earnings Per Share | 5.05 X | ||||
| Price To Earnings To Growth | (1.75) X | ||||
| Target Price | 22.38 | ||||
| Number Of Employees | 10 K | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 4.04 B | ||||
| Total Asset | 12.06 B | ||||
| Retained Earnings | 443 M | ||||
| Working Capital | 1.59 B | ||||
| Annual Yield | 0.07 % | ||||
| Net Asset | 12.06 B | ||||
| Last Dividend Paid | 1.12 |
About Organon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Organon Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organon Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Organon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organon will appreciate offsetting losses from the drop in the long position's value.Moving together with Organon Stock
Moving against Organon Stock
| 0.9 | BMY | Bristol Myers Squibb | PairCorr |
| 0.82 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
| 0.8 | CAH | Cardinal Health | PairCorr |
| 0.71 | ESPR | Esperion Therapeutics | PairCorr |
| 0.64 | XAIR | Beyond Air | PairCorr |
The ability to find closely correlated positions to Organon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organon Co to buy it.
The correlation of Organon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Organon Piotroski F Score and Organon Altman Z Score analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.